1.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ML22780, 2009-014279-37, NCT01094184
|
|
2.
|
Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ML25288, NCT01301729
|
|
3.
|
Phase: Phase IV Type: Diagnostic, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: P0334, NCT01501487
|
|
4.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: Adult Sponsor: Other Protocol IDs: RCOG-MRC-CHORUS, EU-20350, ISRCTN74802813, NCT00075712
|
|
5.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 20 to 85 Sponsor: Other Protocol IDs: AMC0183, NCT00689715
|
|
6.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: OV21, CAN-NCIC-OV21, UCL08/0379, GEICO-0902, SWOG OV.21, CDR0000655241, NCT00993655
|
|
7.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000657121, SINGAPORE-NCC0901, NCC0901, NCT00997906
|
|
8.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TG4010.14/TIME, 8559, NCT01383148
|
|
9.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: CDHA 147937-7, NCT01404156
|
|
10.
|
Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GBG 66, 2011-000553-23, NCT01426880
|
|
11.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 20 and over Sponsor: Other Protocol IDs: GOTIC-001/JGOG3019, UMIN000003670, NCT01506856
|
|
12.
|
Phase: Phase III, Phase II Type: Treatment Status: Approved-not yet active Age: 18 to 80 Sponsor: Other Protocol IDs: CIH-RXB-201205001, NCT01631357
|
|
13.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: SAKK 22/99, SWS-SAKK-22/99, EU-99028, NCT00004935
|
|
14.
|
Phase: Phase III Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: CDR0000068827, IBCSG-22-00, EU-20119, EUDRACT-2005-005666-36, NCT00022516
|
|
15.
|
Phase: Phase III Type: Treatment Status: Active Age: Over 16 Sponsor: Other Protocol IDs: CDR0000416124, FRE-FNCLCC-GETUG-13/0206, EU-20502, NCT00104676
|
|
16.
|
Phase: Phase III Type: Treatment Status: Active Age: Not specified Sponsor: NCI Protocol IDs: GOG-0212, NCT00108745
|
|
17.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 11718, UVACC-ONYX-11718, UVACC-HIC-11860, EUDRACT-2005-0000941-12, BAYER-UVACC-ONYX-11718, NCT00111007
|
|
18.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: 119 of 2003, NCT00193739
|
|
19.
|
Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR005143, EPOANE3010, 2005-001817-17, NCT00338286
|
|
20.
|
Phase: Phase III Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: CDR0000521447; P06.031, CKTO-2006-04, ISRCTN14387080, P06.031-PORTEC-3, 2007-004917-33, CKTO-PORTEC-3, EU-20664, NCT00411138
|
|
21.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 74 Sponsor: NCI Protocol IDs: RTOG-0436, RTOG 0436, NCT00655876
|
|
22.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00587, U10CA027469, CDR0000546714, GOG-0213, NCT00565851
|
|
23.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: MREC-ICON7, EUDRACT-2005-003929-22, ISRCTN91273375, ROCHE-MREC-ICON7, EU-20730, ICON7, MREC-06/MRE02/52, NCT00483782
|
|
24.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CTI-PGT-07-00400, PGT-06-0040(0), EUDRACT-2007-004167-22, NCT00551733
|
|
25.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: AOUMODENA-SHORT-HER, EudraCT 2007-004326-25, EUDRACT-2007-004326-25, EU-20825, NCT00629278
|